Page 171 - Read Online

27. Liu C, Yu H, Zhang Y, Li D, Xing X, Chen L, Zeng X, Xu D, Fan Q, 323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic
Xiao Y, Chen W, Wang Q. Upregulation of miR-34a-5p antagonizes indicators for clinical outcome of glioblastoma patients. J Transl Med
AFB1-induced genotoxicity in F344 rat liver. Toxicon 2015;106:46-56. 2013;11:10.
28. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong 45. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E,
CM. MicroRNA-142-3p and microRNA-142-5p are downregulated Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, Becker KG,
in hepatocellular carcinoma and exhibit synergistic effects on cell Gorospe M, Hide W, Lieberman J. miR-24 inhibits cell proliferation
motility. Front Med 2015;9:331-43. by targeting E2F2, MYC, and other cell-cycle genes via binding
29. Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a to “seedless” 3’UTR microRNA recognition elements. Mol Cell
new regulator of RAC1, suppresses the migration and invasion of 2009;35:610-25.
hepatocellular carcinoma cells. FEBS Lett 2011;585:1322-30. 46. Li YQ, Lu JH, Bao XM, Wang XF, Wu JH, Hong WQ. MiR-24
30. Chiu LY, Kishnani PS, Chuang TP, Tang CY, Liu CY, Bali D, Koeberl functions as a tumor suppressor in nasopharyngeal carcinoma through
D, Austin S, Boyette K, Weinstein DA, Murphy E, Yao A, Chen targeting FSCN1. J Exp Clin Cancer Res 2015;34:130.
YT, Li LH. Identification of differentially expressed microRNAs 47. Ma Y, She XG, Ming YZ, Wan QQ. miR-24 promotes the proliferation
in human hepatocellular adenoma associated with type I glycogen and invasion of HCC cells by targeting SOX7. Tumour Biol
storage disease: a potential utility as biomarkers. J Gastroenterol 2014;35:10731-6.
2014;49:1274-84. 48. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides
31. Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z, Wang GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras
M. Circulating miR-497 and miR-663b in plasma are potential novel M, Iliopoulos D. An HNF4alpha-miRNA inflammatory feedback
biomarkers for bladder cancer. Sci Rep 2015;5:10437. circuit regulates hepatocellular oncogenesis. Cell 2011;147:1233-47.
32. Matamala N, Vargas MT, Gonzalez-Campora R, Miñambres R, Arias JI, 49. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann R Jr, Srikantan
Menéndez P, Andrés-León E, Gómez-López G, Yanowsky K, Calvete- S, Subrahmanyam R, Martindale JL, Yang X, Ahmed F, Navarro F,
Candenas J, Inglada-Pérez L, Martínez-Delgado B, Benítez J. Tumor Dykxhoorn D, Lieberman J, Gorospe M. p16(INK4a) translation
microRNA expression profiling identifies circulating microRNAs for suppressed by miR-24. PLoS One 2008;3:e1864.
early breast cancer detection. Clin Chem 2015;61:1098-106. 50. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y. miR-24 regulates
33. Jiang H, Yu WW, Wang LL, Peng Y. miR-130a acts as a potential apoptosis by targeting the open reading frame (ORF) region of FAF1
diagnostic biomarker and promotes gastric cancer migration, invasion in cancer cells. PLoS One 2010;5:e9429.
and proliferation by targeting RUNX3. Oncol Rep 2015;34:1153-61. 51. Yan SR, Liu ZJ, Yu S, Bao YX. Investigation of the value of miR-21
34. Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P. MiR-130a and in the diagnosis of early stage HCC and its prognosis: a meta-analysis.
MiR-374a function as novel regulators of cisplatin resistance in human Genet Mol Res 2015;14:11573-86.
ovarian cancer A2780 cells. PLoS One 2015;10:e0128886. 52. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li
35. Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y, Han W. The H, Ren X. Diagnostic and prognostic value of circulating miR-21 for
oncogenic role of microRNA-130a/301a/454 in human colorectal cancer: a systematic review and meta-analysis. Gene 2014;533:389-97.
cancer via targeting Smad4 expression. PLoS One 2013;8:e55532.
36. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, 53. Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, Tang
ZH, Huang F. Meta-analysis of microRNA-183 family expression in
Bottoni A, Garofalo M, Gasparini P, Condorelli G, Chiariello M, Croce human cancer studies comparing cancer tissues with noncancerous
CM. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC
by downregulating miR-221 and 222. Oncogene 2012;31:634-42. tissues. Gene 2013;527:26-32.
37. El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy 54. Zhang HD, Jiang LH, Sun DW, Li J, Tang JH. MiR-139-5p: promising
M, Kobaisi MH, Hamed I, Abdel Wahab AH. Investigating the biomarker for cancer. Tumour Biol 2015;36:1355-65.
pretreatment miRNA expression patterns of advanced hepatocellular 55. Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated
carcinoma patients in association with response to TACE treatment. microRNAs in progression of hepatocellular carcinoma: a systematic
Biomed Res Int 2015;2015:649750. review. Hepatol Res 2015; doi: 10.1111/hepr.12606.
38. Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, Wang C, 56. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, Etheridge A, Luo Y,
Xing TY, Xia Q. MicroRNA-24 modulates aflatoxin B1-related Ding Y, Wang K. Current state of circulating microRNAs as cancer
hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int biomarkers. Clin Chem 2015;61:1138-55.
2014;2014:482926. 57. Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag
39. Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski
of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med G, Krawczyk M, Jazdzewski K. Next generation sequencing reveals
Oncol 2014;31:177. microRNA isoforms in liver cirrhosis and hepatocellular carcinoma.
40. Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, Aslan G, Emekdas Int J Biochem Cell Biol 2014;53:208-17.
G, Sezgin O, Altintas E, Tiftik EN. Serum microRNAs; miR-30c-5p, 58. Zhang J, Chong CC, Chen GG, Lai PB. A seven-microRNA expression
miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel signature predicts survival in hepatocellular carcinoma. PLoS One
non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular 2015;10:e0128628.
carcinoma. Mol Biol Rep 2015;42:713-20. 59. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng
41. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L,
Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng Liang A, Tao W, Cao X . Identification of miRNomes in human liver
C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. A serum and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic
microRNA classifier for early detection of hepatocellular carcinoma: a target for hepatocellular carcinoma. Cancer Cell 2011;19:232-43.
multicentre, retrospective, longitudinal biomarker identification study 60. Lopez JP, Diallo A, Cruceanu C, Fiori LM, Laboissiere S, Guillet
with a nested case-control study. Lancet Oncol 2015;16:804-15. I, Fontaine J, Ragoussis J, Benes V, Turecki G, Ernst C. Biomarker
42. Chowdhury JB, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray discovery: quantification of microRNAs and other small non-coding
RB. Hepatitis C virus infection modulates expression of interferon RNAs using next generation sequencing. BMC Med Genomics
stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2015;8:35.
2012;86:10221-5. 61. Knutsen E, Fiskaa T, Ursvik A, Jørgensen TE, Perander M, Lund E,
43. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Seternes OM, Johansen SD, Andreassen M. Performance comparison
Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J. MiR- of digital microRNA profiling technologies applied on human breast
130a, miR-203 and miR-205 jointly repress key oncogenic pathways and cancer cell lines. PLoS One 2013;8:e75813.
are downregulated in prostate carcinoma. Oncogene 2013;32:277-85. 62. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches
44. Qiu SW, Lin S, Hu D, Feng YM, Tan Y, Peng Y. Interactions of miR- and considerations. Nat Rev Genet 2012;13:358-69.

162 Hepatoma Research | Volume 2 | June 1, 2016